Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: ALNY stock price vs PVH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PVH's multiple
Needs PVH P/E.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALNY FY 2025 (ended Dec 31, 2025) · PVH FY 2026 (ended Feb 1, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
Capital structure 60% equity / 40% debt · EV / Revenue 0.56x · EV / EBITDA 10.03x
ALNY carries the larger enterprise value at $38.07B against $5.05B; PVH trades on the lower EV / Revenue multiple (0.56x vs 10.25x); PVH on the lower EV / EBITDA (10.03x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
PVH CORP. · implied price per share
Bear
$67.33
Base
$85.11
Bull
$108.27
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
5.22x
0.48x
Net debt / EBITDA
Leverage against operating earnings
4.13x
3.21x
Cash and equivalents
Liquid reserves on the balance sheet
$1.66B
$701.50M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ALNY vs MRNA
Sarepta Therapeutics, Inc.
ALNY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALNY vs VRTX
BioNTech SE
ALNY vs BNTX
ACADIA PHARMACEUTICALS INC
ALNY vs ACAD
TAPESTRY, INC.
ALNY vs TPR
RALPH LAUREN CORP
ALNY vs RL
Kontoor Brands, Inc.
ALNY vs KTB
GAP INC
ALNY vs GAP
$4.12B
$2.32B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
